End-stage liver disease and liver transplantation: Role of lamivudine therapy in patients with chronic hepatitis B

Journal of Medical Virology

Volumn 61, Issue 3, 2000, Pages 403-408

  Keeffe, Emmet B ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Nucleoside analogue; Prophylaxis; Treatment; YMDD variant

Indexed keywords

IMMUNOGLOBULIN; LAMIVUDINE; NUCLEOSIDE ANALOG;

ARTICLE; CHRONIC HEPATITIS; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FAILURE; LIVER TRANSPLANTATION; PROPHYLAXIS; SURVIVAL RATE; TREATMENT INDICATION;

ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER FAILURE; LIVER TRANSPLANTATION; TREATMENT OUTCOME;

DNA VIRUSES; HEPATITIS B VIRUS;

EID: 0034041445     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-9071(200007)61:3<403::AID-JMV21>3.0.CO;2-5     Document Type: Article

References (38)

1. Andreone P, Caraceni P, Grazi GL, Belli L, Milandri GL, Ercolani G, Jovine E, D'Errico A, Dal Monte PR, Ideo G, Forti D, Mazziotti A, Cavallari A, Bernardi M. 1998. Lamivudine treatment for acute hepatitis B after liver transplantation J Hepatol 29:985-989.
2. Atkins M, Hunt CM, Brown N, Gray F, Sanathanan L, Woessner M, Lai CL, Dusheiko G, Dienstag J, Wright T, Barnard J, Bourne E, Condreay L. 1998. Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients. Hepatology 28:319A (Abstract).
3. Ben-Ari Z, Shmueli D, Mor E, Shapira Z, Tur-Kaspa R. 1997. Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation 63:393-396.
4. Chang C-N, Skalski V, Zhou JH, Cheng YC. 1992. Biochemical pharmacology of (+)-and (-)-2′,3′-dideoxy-3′-thiacytidine as antihepatitis B virus agents. J Biol Chem 267:22414-22420.
5. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. 1992. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 103:1630-1635.
6. Dienstag J, Schiff E, Wright T, Perrillo R, Hann H-W, Crowther L, Woessner M, Rubin M, Brown N, and the U.S. Lamivudine Investigator Group. 1998. Lamivudine treatment for one year in previously untreated U.S. hepatitis B patients: histologic improvement and hepatitis Be-antigen (HBeAg) seroconversion. Gastroenterology 114:A1235 (Abstract).
7. Dodson SF, Balan Y, Shakil O, Bonham A, Rakela J, Fung JJ. 1998. Combination HBIG and lamivudine after liver transplantation for hepatitis B related liver disease. Hepatology 28:733A (Abstract).
8. Furman PA, Davis M, Liotta DC, Paff M, Frick LW, Nelson DJ, Dornsife RE, Wurster JA, Wilson LJ, Fyfe JA, Tuttle JV, Miller WH, Condreay L, Averett DR, Schinazi RF, Painter GR. 1992. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother 36: 2686-2692.
9. Gish RG, Lau JYN, Brooks L, Fang JWS, Steady SL, Imperial JC, Garcia-Kennedy R, Esquivel CO, Keeffe EB. 1996. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 23:1-7.
10. Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, McMaster P, Beranek P, Kennedy F, Kibbler H, McPhillips P, Elias E, Dusheiko G. 1996. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348:1212-1215.
11. Han S-H, Martin P, Markowitz J, Holt C, Artinian L, Kunder G, Goldstein LI, GOSS J, Seu P, Busuttil RW. 1998. Long-term combination HBIG and lamivudine is highly effective in preventing recurrent hepatitis B in orthotopic liver transplant (OLT) recipients. Hepatology 28:222A (Abstract).
12. Ho BM, So SK, Esquivel CO, Keeffe EB. 1997. Liver transplantation in Asian patients with chronic hepatitis B. Hepatology 25:223-225.
13. Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. 1993. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 104:1116-1121.
14. Johnson MA, Horak J, Breuel P. 1998. The pharmacokinetics of lamivudine in patients with impaired hepatic function. Eur J Clin Pharmacol 54:363-366.
15. König V, Hopf U, Neuhaus P, Bauditz J, Schmidt CA, Blumhardt G, Beckstein W-O, Neuhaus R, Lobeck H. 1994. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 58:553-559.
16. Krüger M, Tillmann HL, Trautwein C, Bode U, Oldhafer K, Maschek H, Böker KH, Broelsch CE, Pichlmayr R, Manns MP. 1996. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. Liver Transpl Surg 2:253-262.
17. Lai C-L, Chien R-N, Leung NW, Chang T-T, Guan R, Tai D-I, Ng K-Y, Wu P-C, Dent JC, Barber J, Stephenson SL, Gray DF. 1998. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339:61-68.
18. Leung N, Dienstag J, Schiff E, Sullivan M, Atkins M, Grice R, Woessner M, Brown N, Hunt CM. 1998. Clinical safety profile of lamivudine treatment in a large cohort of hepatitis B patients. Hepatology 28:587A (Abstract).
19. Markowitz J, Pakrasi A, Hollis P, Martin P, Goldstein L, Busuttil R. 1996. Efficacy of lamivudine for prophylaxis and treatment of hepatitis B in liver transplant patients. Hepatology 24:182A (Abstract).
20. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, Goss JA, Schmidt P, Pakrasi A, Artinian L, Murray NG, Imagawa DK, Holt C, Goldstein LI, Stribling R, Busuttil RW. 1998. Prophylaxis against hepatitis B recurrence after liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28:585-589.
21. Marzano A, Debernardi-Venon W, Actis GC, Leone N, Ghisetti V, Smedile A, Zamboni F, Franchello A, David E, Salizzoni M, Rizzetto M. 1999. Efficacy of lamivudine treatment associated with low-dose immunoprophylaxis on HBV recurrence after liver transplantation. J Hepatol 30:80 (Abstract).
22. McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, Caldwell SH, Pruett TL. 1996. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunisation. Transplantation 61:1358-1364.
23. Naumann U, Protzer-Knolle U, Berg T, Leder K, Lobeck H, Bechstein WO, Gerken G, Hopf U, Neuhaus P. 1997. A pretransplant infection with precore mutants of hepatitis B virus does not influence the outcome of orthotopic liver transplantation in patients on high dose anti-hepatitis B virus surface antigen immunoprophylaxis. Hepatology 26:478-484.
24. Nery JR, Weppler D, Rodriguez M, Ruiz P, Schiff ER, Tzakis AG. 1998. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 65:1615-1621.
25. Pasha TM, Douglas DD, Krom RA, Wiesner RH. 1998. Costeffectiveness of lamivudine and hepatitis B immunoglobulin after liver transplantation for hepatitis B. Hepatology 28:348A (Abstract).
26. Perrillo RP. 1993. Interferon in the management of chronic hepatitis B. Dig Dis Sci 38:577-593.
27. Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, Caldwell S, Schiff E, Gish R, Villeneuve JP, Farr G, Anschuetz G, Crowther L, Brown N. 1999a. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 29:1581-1586.
28. Perrillo RP, Schiff ER, Dienstag JL, Gish RG, Dickson RC, Adams PC, Brown NA, Gardner SD, Anschuetz GC. 1999b. Lamivudine for suppression of viral replication in patients with decompensated chronic hepatitis B. Hepatology 30:301A (Abstract).
29. Perrillo RP, Schiff ER, Dienstag JL, Gish RG, Dickson RC, Adams PC, Brown NA, Gardner SD, Anschuetz GC. 1999c. Lamivudine for prevention of recurrent hepatitis B after liver transplantation: final results of a U.S./Canadian multicenter trial. Hepatology 30: 222A (Abstract).
30. Roche B, Samuel D, Roque AM, Feray C, Petit AM, Vasseur B, Gigou M, Arulnaden JL, Bismuth A, Reynes M, Dussaix E, Bismuth H. 1999. Intravenous anti HBsIg combined with oral lamivudine for prophylaxis against HBV recurrence after liver transplantation. J Hepatol 30:80 (Abstract).
31. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou J-P, Bismuth H, and the Investigators of the European Concerted Action on Viral Hepatitis Study. 1993. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329:1842-1847.
32. Schiff E, Karayalcin S, Grimm I, Perrillo R, Dienstag J, Husa P, Schalm S, Crowther L, Sullivan M, Woessner M, McPhillips P, Brown N, and the International Lamivudine Investigator Group. 1998. A placebo controlled study of lamivudine hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 29:889-896.
33. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, Ascher NL, Wright TL. 1996. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 24:1327-1333.
34. Terrault NA, Wright TL, Roberts JP, Ascher NL. 1998. Combined short-term hepatitis B immunoglobulin (HBIG) and long-term lamivudine (LAM) versus HBIG monotherapy as hepatitis B virus (HBV) prophylaxis in liver transplant recipients. Hepatology 28: 389A (Abstract).
35. Terrault NA. 1999. Hepatitis B virus and liver transplantation. Clin Liver Dis 3:389-415.
36. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. 1991. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 13:619-626.
37. Van Thiel DH, Friedlander L, Kania RJ, Molloy PJ, Hassanein T, Wahlstrom E, Faruki H. 1997. Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B. Hepatogastroenterology 44:808-812.
38. Villeneuve JP, Bilodeau M, Fenyves D, Pomier G, Pilon D, Raymond G, Willems B. 1997. Suppression of hepatitis B virus replication by lamivudine results in improvement of liver function in patients with severe cirrhosis. Hepatology 26:430A (Abstract).